Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis".
Attauabi Mohamed, Seidelin Jakob Benedict, Burisch Johan·Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Abstract not available